Enlivex Therapeutics (ENLV) PT Raised to $80 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Enlivex Therapeutics (NASDAQ: ENLV) to $80.00 (from $20.00) while maintaining a Buy rating.

The analyst commented: "We draw investors' attention to the fact that the price of the RAIN token has risen over 3,000% over a one-year period, while in the past 90 days its price has increased by ~63%. In our view, this reflects rapidly accelerating volume expansion on the RAIN protocol. Enlivex last month effected a 1-for-15 reverse split of its common stock to regain compliance with the minimum bid price on the NASDAQ Capital Market exchange. In accordance with this, and following the announcement of a $400M private placement, we reiterate our Buy rating, while adjusting our 12-month price target to $80 from the prior $20 per share."

You May Also Be Interested In

• Morgan Stanley Double Downgrades Gujarat Energy (GUJENERG:IN) to Underweight
• Jefferies Reiterates Buy Rating on Intuit (INTU)
• After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO